Bank of New York Mellon
ARCT icon

Bank of New York Mellon’s Arcturus Therapeutics ARCT Stock Holding History

Bank of New York Mellon’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$540K Buy
80,314
+5,317
+7% +$41.9K ﹤0.01% 3715
2026
Q1 		$579K Sell
74,997
-1,304
-2% -$9.52K ﹤0.01% 3527
2025
Q4 		$468K Sell
76,301
-12,368
-14% -$134K ﹤0.01% 3647
2025
Q3 		$1.63M Buy
88,669
+3,789
+4% +$60.9K ﹤0.01% 2925
2025
Q2 		$1.1M Buy
84,880
+9,951
+13% +$118K ﹤0.01% 3079
2025
Q1 		$793K Sell
74,929
-3,251
-4% -$51.6K ﹤0.01% 3188
2024
Q4 		$1.33M Sell
78,180
-22,024
-22% -$415K ﹤0.01% 2974
2024
Q3 		$2.33M Sell
100,204
-18,977
-16% -$406K ﹤0.01% 2679
2024
Q2 		$2.9M Buy
119,181
+3,578
+3% +$109K ﹤0.01% 2592
2024
Q1 		$3.9M Sell
115,603
-17,316
-13% -$614K ﹤0.01% 2437
2023
Q4 		$4.19M Buy
132,919
+38,492
+41% +$915K ﹤0.01% 2460
2023
Q3 		$2.41M Buy
94,427
+3,587
+4% +$110K ﹤0.01% 2701
2023
Q2 		$2.61M Buy
90,840
+15,499
+21% +$422K ﹤0.01% 2684
2023
Q1 		$1.81M Sell
75,341
-1,241
-2% -$22.3K ﹤0.01% 2858
2022
Q4 		$1.3M Buy
76,582
+986
+1% +$17.2K ﹤0.01% 3069
2022
Q3 		$1.12M Buy
75,596
+6,711
+10% +$113K ﹤0.01% 3149
2022
Q2 		$1.08M Sell
68,885
-8,885
-11% -$174K ﹤0.01% 3178
2022
Q1 		$2.1M Sell
77,770
-268
-0.3% -$6.84K ﹤0.01% 2907
2021
Q4 		$2.89M Buy
78,038
+1,261
+2% +$51.4K ﹤0.01% 2765
2021
Q3 		$3.67M Buy
76,777
+6,008
+8% +$269K ﹤0.01% 2645
2021
Q2 		$2.4M Sell
70,769
-3,016
-4% -$102K ﹤0.01% 2874
2021
Q1 		$3.05M Sell
73,785
-7,428
-9% -$443K ﹤0.01% 2674
2020
Q4 		$3.52M Buy
81,213
+18,424
+29% +$1.25M ﹤0.01% 2528
2020
Q3 		$2.69M Buy
62,789
+9,897
+19% +$491K ﹤0.01% 2509
2020
Q2 		$2.47M Buy
+52,892
New +$1.82M ﹤0.01% 2552

Other funds holding ARCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon's ARCT Position: Q2 2026 in Review

Bank of New York Mellon increased its Arcturus Therapeutics (ARCT) stake by 7.1% in Q2 2026, buying an estimated $41.9K and bringing the position to 80,314 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #3715.

Bank of New York Mellon first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $4.19M in Q4 2023. 61 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Bank of New York Mellon held 80,314 shares of Arcturus Therapeutics worth $540K as of Q2 2026.
  • Bank of New York Mellon bought 5,317 Arcturus Therapeutics shares in Q2 2026, an estimated $41.9K.
  • Arcturus Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3715 holding.
  • Bank of New York Mellon first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Bank of New York Mellon's Arcturus Therapeutics position peaked at $4.19M in Q4 2023.
  • 61 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.